Pathogenesis and Treatment of Sjogren's Syndrome: Review and Update

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Feb 23

PMID 36817420

Authors

Qipeng Zhan

Jianan Zhang

Yubin Lin

Wenjing Chen

Xinzou Fan

Dunfang Zhang

Affiliations

Soon will be listed here.

Abstract

Sjogren's syndrome (SS) is a chronic autoimmune disease accompanied by multiple lesions. The main manifestations include dryness of the mouth and eyes, along with systemic complications (e.g., pulmonary disease, kidney injury, and lymphoma). In this review, we highlight that IFNs, Th17 cell-related cytokines (IL-17 and IL-23), and B cell-related cytokines (TNF and BAFF) are crucial for the pathogenesis of SS. We also summarize the advances in experimental treatment strategies, including targeting Treg/Th17, mesenchymal stem cell treatment, targeting BAFF, inhibiting JAK pathway, et al. Similar to that of SLE, RA, and MS, biotherapeutic strategies of SS consist of neutralizing antibodies and inflammation-related receptor blockers targeting proinflammatory signaling pathways. However, clinical research on SS therapy is comparatively rare. Moreover, the differences in the curative effects of immunotherapies among SS and other autoimmune diseases are not fully understood. We emphasize that targeted drugs, low-side-effect drugs, and combination therapies should be the focus of future research.

Citing Articles

Identification of Epigenetic Alteration of the IFI44L Gene in B Cells of Sjogren's Syndrome as a Clinical Biomarker and Molecular Significance.

Zhang K, Luo Z, Yao X, Lu D, Hong T, Zhu X J Inflamm Res. 2025; 18:2499-2512.

PMID: 39991660 PMC: 11847453. DOI: 10.2147/JIR.S503309.

Regenerative fibroblasts derived from autologous skin tissue for the treatment of Sjögren's syndrome: a case report.

Ma Z, Wu X, Cao L, Jiao C, Ma D, Zhao Y Front Immunol. 2025; 16:1529883.

PMID: 39931068 PMC: 11808821. DOI: 10.3389/fimmu.2025.1529883.

Mesenchymal Stem Cell-Sourced Exosomes as Potentially Novel Remedies for Severe Dry Eye Disease.

Harrell C, Djonov V, Volarevic A, Arsenijevic A, Volarevic V J Ophthalmol. 2025; 2025():5552374.

PMID: 39839752 PMC: 11748739. DOI: 10.1155/joph/5552374.

Psoriasis increases the risk of Sjögren's syndrome: evidence from a propensity score-matched cohort study and transcriptomic analysis.

Kang Z, Du Y, Cui R, Wang Q, Chen M, Wang Y BMC Med. 2025; 23(1):26.

PMID: 39838439 PMC: 11752802. DOI: 10.1186/s12916-025-03856-y.

Fecal metabolomic analysis of the role of gut microbiota and short-chain fatty acids in the therapeutic mechanism of Timosaponin AIII in Sjögren's syndrome.

Pang F, Jiang Q, Tang X, Li K Clin Rheumatol. 2025; 44(3):1209-1223.

PMID: 39826048 PMC: 11865223. DOI: 10.1007/s10067-024-07294-8.

References

Cluxton D, Petrasca A, Moran B, Fletcher J . Differential Regulation of Human Treg and Th17 Cells by Fatty Acid Synthesis and Glycolysis. Front Immunol. 2019; 10:115. PMC: 6369198. DOI: 10.3389/fimmu.2019.00115. View

Bossini N, Savoldi S, Franceschini F, Mombelloni S, Baronio M, Cavazzana I . Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant. 2001; 16(12):2328-36. DOI: 10.1093/ndt/16.12.2328. View

Pardanani A, Laborde R, Lasho T, Finke C, Begna K, Al-Kali A . Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013; 27(6):1322-7. PMC: 3677140. DOI: 10.1038/leu.2013.71. View

Edwards J, Cambridge G . Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001; 40(2):205-11. DOI: 10.1093/rheumatology/40.2.205. View

Powell J, Lerner C, Schwartz R . Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol. 1999; 162(5):2775-84. View

Kolbinger F, Loesche C, Valentin M, Jiang X, Cheng Y, Jarvis P . β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2016; 139(3):923-932.e8. DOI: 10.1016/j.jaci.2016.06.038. View

Haseeb M, Pirzada R, Ain Q, Choi S . Wnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics. Cells. 2019; 8(11). PMC: 6912555. DOI: 10.3390/cells8111380. View

Wei F, Chang Y, Wei W . The role of BAFF in the progression of rheumatoid arthritis. Cytokine. 2015; 76(2):537-544. DOI: 10.1016/j.cyto.2015.07.014. View

Fox R . The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology. 2002; 58(10):1576; author reply 1576. DOI: 10.1212/wnl.58.10.1576. View

10.

Meiners P, Vissink A, Kroese F, Spijkervet F, Smitt-Kamminga N, Abdulahad W . Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014; 73(7):1393-6. DOI: 10.1136/annrheumdis-2013-204653. View

11.

Carrillo-Ballesteros F, Palafox-Sanchez C, Franco-Topete R, Munoz-Valle J, Orozco-Barocio G, Martinez-Bonilla G . Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures. Clin Exp Med. 2020; 20(4):615-626. DOI: 10.1007/s10238-020-00637-0. View

12.

Sambataro G, Ferro F, Orlandi M, Sambataro D, Torrisi S, Quartuccio L . Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: A systematic review from the Italian Society of Rheumatology. Autoimmun Rev. 2019; 19(2):102447. DOI: 10.1016/j.autrev.2019.102447. View

13.

Fletcher J, Lalor S, Sweeney C, Tubridy N, Mills K . T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010; 162(1):1-11. PMC: 2990924. DOI: 10.1111/j.1365-2249.2010.04143.x. View

14.

Shi B, Qi J, Yao G, Feng R, Zhang Z, Wang D . Mesenchymal stem cell transplantation ameliorates Sjögren's syndrome via suppressing IL-12 production by dendritic cells. Stem Cell Res Ther. 2018; 9(1):308. PMC: 6225717. DOI: 10.1186/s13287-018-1023-x. View

15.

Bowman S, Everett C, ODwyer J, Emery P, Pitzalis C, Ng W . Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol. 2017; 69(7):1440-1450. DOI: 10.1002/art.40093. View

16.

Charras A, Arvaniti P, Le Dantec C, Dalekos G, Zachou K, Bordron A . JAK Inhibitors and Oxidative Stress Control. Front Immunol. 2019; 10:2814. PMC: 6908489. DOI: 10.3389/fimmu.2019.02814. View

17.

Karatas A, Omercikoglu Z, Oz B, Dagli A, Catak O, Erman F . Wnt signaling pathway activities may be altered in primary Sjogren’s syndrome. Turk J Med Sci. 2021; 51(4):2015-2022. PMC: 8569792. DOI: 10.3906/sag-2102-367. View

18.

Laplante M, Sabatini D . mTOR signaling in growth control and disease. Cell. 2012; 149(2):274-93. PMC: 3331679. DOI: 10.1016/j.cell.2012.03.017. View

19.

Silva F, Rodrigues B, Ayrizono M, Leal R . The Immunological Basis of Inflammatory Bowel Disease. Gastroenterol Res Pract. 2017; 2016:2097274. PMC: 5192315. DOI: 10.1155/2016/2097274. View

20.

Alexander E, Provost T, STEVENS M, Alexander G . Neurologic complications of primary Sjögren's syndrome. Medicine (Baltimore). 1982; 61(4):247-57. DOI: 10.1097/00005792-198207000-00004. View